



**COUNCIL OF  
THE EUROPEAN UNION**

**Brussels, 15 May 2014  
(OR. en)**

**9893/14**

**CORDROGUE 34  
COLAC 23**

## **OUTCOME OF PROCEEDINGS**

---

From:	General Secretariat of the Council
On:	6 May 2014
To:	Meeting of Technical Committee of the EU-CELAC Mechanism on Drugs
Subject:	Summary of discussions

---

### **1. Adoption of the agenda**

The meeting adopted the agenda as set out in doc. **CM 2521/14**.

### **2. Preparation of the XVIth High Level meeting of the EU-CELAC Coordination and Cooperation Mechanism on Drugs**

The EU co-Presidency updated the meeting about some practical details related with the above-mentioned meeting to be held in Athens on 18-19 June 2014 and introduced the preliminary agenda of the meeting. The representative of the EEAS informed the delegations about the meetings on drug precursors to be held back-to-back with the EU-CELAC High Level meeting.

The delegations agreed that two thematic debates would be held during the forthcoming High Level meeting: "Institutionality looks at a public health and human rights approach to the world drug problem" proposed by the CELAC side and "New psychoactive substances" proposed by the EU side. It was also agreed that each side would make one presentation during each thematic debate and that the EU delegate would moderate the thematic debate on institutionality, while the CELAC delegate would moderate the thematic debate on new psychoactive substances.

The CELAC delegates were invited to suggest additional presentations/information points to be presented during the High Level meeting.

The CELAC co-Presidency presented the progress achieved on negotiating the draft Athens declaration (doc. DS 1046/3/14 REV 3) on the CELAC side and promised to provide the comments on the whole text of the Declaration as well as the comments on the draft Annual report (doc. DS 1146/14) after the forthcoming intra-CELAC meetings. The CELAC delegations expressed their interest in receiving the reports mentioned in the Annual report.

### **3. Any other business**

No items were discussed under this point.

---